{"corpus_id":251998037,"paper_sha":"003807ea3c24cfcc34725130924de69db195384a","doi":"10.1155/2022/9005804","arxiv_id":null,"pmid":36081666,"pmcid":"9448536","mag_id":null,"dblp_id":null,"acl_id":null,"title":"Synergistic Lethality Effects of Apatinib and Homoharringtonine in Acute Myeloid Leukemia","year":2022,"publication_date":"2022-08-30","venue":"Journal of Oncology","journal":{"name":"Journal of Oncology","pages":null,"volume":"2022"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":48,"citation_count":3,"influential_citation_count":0,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":null,"chemicals":null,"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://downloads.hindawi.com/journals/jo/2022/9005804.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/003807ea3c24cfcc34725130924de69db195384a","s2_open_access_license":"CCBY","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Purpose The significance of vascular endothelial growth factor receptor (VEGFR)-2 in numerous solid tumors and acute myeloid leukemia (AML) has been demonstrated, but Apatinib remains largely unexplored. In this study, whether Apatinib combined with homoharringtonine (HHT) kills AML cell lines and its possible mechanisms have been explored. Methods AML cell lines were treated with Apatinib and HHT in different concentrations with control, Apatinib alone, HHT alone, and Apatinib combined with HHT. The changes of IC50 were measured by CCK8 assay, and apoptosis rate, cell cycle, and the mitochondrial membrane potential in each group were measured by flow cytometry. Finally, the possible cytotoxicity mechanism was analyzed by Western blotting. Results Our results noted that Apatinib combined with HHT remarkably inhibited cell proliferation, reduced the capacity of colony-forming, and induced apoptosis and cell cycle arrest in AML cells. Mechanistically, Apatinib and HHT play a role as a suppressor in the expression of VEGFR-2 and the downstream signaling cascades, such as the PI3K, MAPK, and STAT3 pathways. Conclusion Our preclinical data demonstrate that Apatinib combined with HHT exerts a better antileukemia effect than Apatinib alone by inhibiting the VEGFR-2 signaling pathway, suggesting the potential role of Apatinib and HHT in the treatment of AML. This study provides clinicians with innovative combination therapies and new therapeutic targets for the treatment of AML.","claims":[{"public_id":"cl_0254c6c7fa228f55922773e13ead0ee2","status":"active","text":"Apatinib and homoharringtonine suppress VEGFR-2 expression and downstream PI3K, MAPK, and STAT3 signaling cascades in acute myeloid leukemia cells.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_0254c6c7fa228f55922773e13ead0ee2"},{"public_id":"cl_ac9b31366f8e13f0501b64650e4735ba","status":"active","text":"Apatinib combined with homoharringtonine exerts a better antileukemia effect than apatinib alone in preclinical acute myeloid leukemia models.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_ac9b31366f8e13f0501b64650e4735ba"},{"public_id":"cl_8649c323fc538e18e129e9d37a8bf55d","status":"active","text":"Apatinib combined with homoharringtonine markedly inhibits proliferation, reduces colony-forming capacity, and induces apoptosis and cell cycle arrest in acute myeloid leukemia cells.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_8649c323fc538e18e129e9d37a8bf55d"},{"public_id":"cl_2cb13b98a4f2c0d3e7cef8cc846f23ac","status":"active","text":"VEGFR-2 is identified as a therapeutic target linked to the observed combination effect in acute myeloid leukemia cells.","confidence":0.84,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_2cb13b98a4f2c0d3e7cef8cc846f23ac"}],"concepts":[{"public_id":"co_19506163de4f3f4f8656a3ba8c9d9bdc","status":"active","name":"VEGFR-2 signaling pathway","description":"A receptor-tyrosine-kinase signaling pathway centered on vascular endothelial growth factor receptor 2.","types":["signaling pathway"],"aliases":["vascular endothelial growth factor receptor-2","VEGFR2"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_19506163de4f3f4f8656a3ba8c9d9bdc"},{"public_id":"co_1c609b9da25e3843784f5ce3f7b9e999","status":"active","name":"PI3K pathway","description":"A downstream intracellular signaling pathway involving phosphoinositide 3-kinase.","types":["signaling pathway"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1c609b9da25e3843784f5ce3f7b9e999"},{"public_id":"co_72a6b46a95baead0e3cf41e1dec48499","status":"active","name":"MAPK pathway","description":"A mitogen-activated protein kinase signaling cascade involved in cell regulation.","types":["signaling pathway"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_72a6b46a95baead0e3cf41e1dec48499"},{"public_id":"co_77007e36373ae4bb6a07ce476802c3a2","status":"active","name":"apoptosis","description":"Programmed cell death measured in the treated leukemia cells.","types":["cellular process"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_77007e36373ae4bb6a07ce476802c3a2"},{"public_id":"co_847a60003f984ca8fa9b14be6ce406d9","status":"active","name":"antileukemia effect","description":"Activity that reduces or suppresses leukemia cell growth and survival.","types":["therapeutic effect"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_847a60003f984ca8fa9b14be6ce406d9"},{"public_id":"co_8540d3b167378285fe0b010ebcdadaed","status":"active","name":"apatinib","description":"A small-molecule VEGFR-2 inhibitor evaluated here as an antileukemia agent.","types":["drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8540d3b167378285fe0b010ebcdadaed"},{"public_id":"co_9abfe4092a8fcff30aa02768938ef416","status":"active","name":"cell cycle arrest","description":"A blockage or halt in cell-cycle progression in the treated cells.","types":["cellular process"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9abfe4092a8fcff30aa02768938ef416"},{"public_id":"co_b5e2aa208272f607edaebdee8c572b7b","status":"active","name":"STAT3 pathway","description":"A signal transducer and activator of transcription 3 signaling cascade.","types":["signaling pathway"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b5e2aa208272f607edaebdee8c572b7b"},{"public_id":"co_b84ca96c8c70824a9413d8b28adc169f","status":"active","name":"colony-forming capacity","description":"The ability of leukemia cells to form colonies in culture.","types":["cellular phenotype"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b84ca96c8c70824a9413d8b28adc169f"},{"public_id":"co_bb2a7dd18cc7bf3806c0c3d895638f47","status":"active","name":"cell proliferation","description":"The growth and increase in number of leukemia cells.","types":["cellular process"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_bb2a7dd18cc7bf3806c0c3d895638f47"},{"public_id":"co_c8a9a2c1c9a7ade3a48ac179d1d425cd","status":"active","name":"apatinib combined with homoharringtonine","description":"The drug combination of apatinib and homoharringtonine tested for antileukemia activity.","types":["combination therapy"],"aliases":["Apatinib and HHT","Apatinib combined with HHT"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c8a9a2c1c9a7ade3a48ac179d1d425cd"},{"public_id":"co_fe35e2dbe624d8e44cdcd7f41cfca364","status":"active","name":"acute myeloid leukemia","description":"A malignant hematologic cancer of myeloid precursor cells.","types":["disease"],"aliases":["AML"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_fe35e2dbe624d8e44cdcd7f41cfca364"}],"external_ids":{"DOI":"10.1155/2022/9005804","ArXiv":null,"PubMed":36081666,"PubMedCentral":"9448536","MAG":null,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://downloads.hindawi.com/journals/jo/2022/9005804.pdf","landing_url":"https://www.semanticscholar.org/paper/003807ea3c24cfcc34725130924de69db195384a","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":633719,"paper_uid":"c7650141-bef8-4a23-95f6-389eda2c9125","canonical_identity":{"paper_id":633719,"paper_uid":"c7650141-bef8-4a23-95f6-389eda2c9125","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/251998037"}